Results 31 to 40 of about 106,775 (245)

Exendin-4 attenuates pain-induced cognitive impairment by alleviating hippocampal neuroinflammation in a rat model of spinal nerve ligation

Neural Regeneration Research, 2020
Glucagon-like peptide-1 receptor has anti-apoptotic, anti-inflammatory, and neuroprotective effects. It is now recognized that the occurrence and development of chronic pain are strongly associated with anti-inflammatory responses; however, it is not ...
Shan-Shan Cui, Xiao-Bo Feng, Bing-Hong Zhang, Zhong-Yuan Xia, Li-Ying Zhan   +4 more
doaj   +1 more source

Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an increased risk of fractures. Reduced blood supply and bone strength may contribute to this skeletal fragility.
Andreozzi, Anetzberger, Anichini, Aoyama, Baggio, Balint, Ban, Beckman, Bouxsein, Brunton, Chen, Coleman, Dempster, Ealey, Eckel, Feng, Flatt, Friedman, Griffith, Griffith, Hamilton, Hu, Karim, Kim, Lee, Lu, Ma, Mabilleau, Mabilleau, Mansur, Marenzana, Mieczkowska, Napoli, Nuche-Berenguer, Nuche-Berenguer, Nuche-Berenguer, Nystrom, Nystrom, Odgaard, Okerson, Orland, Orriss, Paschalis, Pereira, Pereira, Prisby, Richard, Roche, Roszer, Schalkwijk, Scheller, Selley, Shymkiw, Smits, Stabley, Sun, Tartaglia, Upadhyay, van Bloemendaal, Vijan, Williams, Wu, Yamamoto, Yamamoto, Yamamoto   +64 more
core   +6 more sources

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1

International Journal of Endocrinology, 2015
The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels.
XingChun Wang, Huan Liu, Jiaqi Chen, Yan Li, Shen Qu   +4 more
doaj   +1 more source

GLP1R rs3765467 Polymorphism Is Associated with the Risk of Early Onset Type 2 Diabetes

International Journal of Endocrinology, 2023
Objective. To investigate the relationship between glucagon-like peptide-1 receptor gene polymorphisms and susceptibility to early onset type 2 diabetes. Methods.
Yunyun Fang, Jingjing Zhang, Linlin Ji, Chaoyu Zhu, Yuanyuan Xiao, Qingge Gao, Wenjing Song, Li Wei   +7 more
doaj   +1 more source

The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling [PDF]

, 2016
Glucagon-like peptide-1 (7–36)amide (GLP-1) plays a central role in regulating blood sugar levels and its receptor, GLP-1R, is a target for anti-diabetic agents such as the peptide agonist drugs exenatide and liraglutide.
Adelhorst, Al-Sabah, Baggio, Beinborn, Biasini, Chen, Chen, Cheng, Coopman, Dan Donnelly, DeFronzo, Di Paolo, Donnelly, Drucker, Hoang, Hollenstein, Inooka, Kieffer, Knudsen, Koole, Koole, Koole, López de Maturana, López de Maturana, Mann, Mann, Mayo, Miller, Monaghan, Moon, Parthier, Perret, Pioszak, Rachel L. Dods, Roberts, Rodrigues, Runge, Runge, Sanchez, Siu, Solano, Tibaduiza, Turton, Underwood, Vertongen, Vilardaga, Wettergren, Wootten, Xiao, Yang, Ørskov   +50 more
core   +1 more source

Glucagon‐like peptide‐1 receptor expression in the human eye [PDF]

Diabetes, Obesity and Metabolism, 2018
Semaglutide is a human glucagon‐like peptide‐1 (GLP‐1) analogue that is in development for the treatment of type 2 diabetes. In the pre‐approval cardiovascular outcomes trial SUSTAIN 6, semaglutide was associated with a significant increase in the risk of diabetic retinopathy (DR) complications vs placebo.
Josephine B. Hebsgaard, Charles Pyke, Emre Yildirim, Lotte B. Knudsen, Steffen Heegaard, Peter H. Kvist   +5 more
openaire   +4 more sources

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors

Physiological Reports, 2017
Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone increasing postprandial insulin release. GLP‐1 also induces diuresis and natriuresis in humans and rodents. The GLP‐1 receptor is extensively expressed in the renal vascular tree in normotensive rats
Jonas Ronn, Elisa P. Jensen, Nicolai J. Wewer Albrechtsen, Jens Juul Holst, Charlotte M. Sorensen   +4 more
doaj   +1 more source

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study

Journal of Diabetes Investigation, 2022
Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) might be less effective in patients with severe hyperglycemia, because hyperglycemia downregulated the GLP‐1 receptor in an animal study.
Yumie Takeshita, Yuki Kita, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Chisato Teramura, Yasufumi Enyama, Toshinari Takamura, the Establishment of Rationale for Antiaging Diabetic Medicine (ERA‐DM) Study Group   +8 more
doaj   +1 more source

In Vivo Imaging of Transplanted Islets with ^(64)Cu-DO3A-VS-Cys^(40)-Exendin-4 by Targeting GLP-1 Receptor [PDF]

, 2011
Glucagon-like peptide 1 receptor (GLP-1R) is highly expressed in pancreatic islets, especially on β-cells. Therefore, a properly labeled ligand that binds to GLP-1R could be used for in vivo pancreatic islet imaging.
Bading, James R., Colcher, David, Conti, Peter E., Fraser, Scott E., Ishiyama, Kohei, Kandeel, Fouad, Li, Lin, Li, Zibo, Nair, Indu, Shively, John E., Todorov, Ivan, Wu, Zhanhong   +11 more
core   +2 more sources

Insulin-like growth factor-1 is a negative modulator of glucagon secretion [PDF]

, 2017
Glucagon secretion involves a combination of paracrine, autocrine, hormonal, and autonomic neural mechanisms. Type 2 diabetes often presents impaired glucagon suppression by insulin and glucose.
Andreozzi, F, Di Fatta, C, Fuoco, A, Mancuso, E, Mannino, Gc, Sesti, G, Spiga, R   +6 more
core   +1 more source